A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged

Aging

Volumn 7, Issue 12, 2015, Pages 1077-1085

  Kannan, Senthil ^a,b   Kossenkov, Andrew ^a   Kurupati, Raj K ^a   Xiang, Jason Z Q ^a   Doyle, Susan A ^c,d   Schmader, Kenneth E ^c,d   Schowe, Louise ^a   Ertl, Hildegund C ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Antibody responses; Gene expression arrays; Influenza vaccine; Timing of vaccination

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

AGED; BLOOD; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; MALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE;

EID: 84958167655     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100852     Document Type: Article

References (18)

1. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine. 2002; 20: 1831-1836.
2. Centers for Disease Control and Prevention (CDC). Influenza activity-United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2013; 62: 473-479.
3. Kelvin DJ, Farooqui A. Extremely low vaccine effectiveness against influenza H3N2 in the elderly during the 2012/2013 flu season. J Infect Dev Ctries. 2013; 7: 299-301.
4. van Essen GA, Beran J, Devaster JM, Durand C, Duval X, Esen M, Falsey AR, Feldman G, Gervais P, Innis BL, Kovac M, Launay O, Leroux-Roels G, et al. Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or nonadjuvanted inactivated trivalent seasonal influenza vaccines. Influenza Other Respir Viruses. 2014; 8: 452-462.
5. DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine. 2013; 31: 861-866.
6. Saitou N, Nei M. Polymorphism and evolution of influenza A virus genes. Mol Biol Evol. 1986; 3:57-74.
7. Webster RG, Hinshaw VS, Bean WJ Jr. Antigenic shift in myxoviruses. Med Microbiol Immunol. 1977; 164: 57-68.
8. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011; 470: 543-547.
9. Puig-Barberà J, Natividad-Sancho A, Launay O, Burtseva E, Ciblak MA, Tormos A, Buigues-Vila A, Martínez-úbeda S, Sominina A; GIHSN Group. 2012-2013 Seasonal Influenza Vaccine Effectiveness against Influenza Hospitalizations: Results from the Global Influenza Hospital Surveillance Network. PLoS One. 2014; 9: e100497.
10. Tan Y, Tamayo P, Nakaya H, Pulendran B, Mesirov JP, Haining WN. Gene signatures related to B-cell proliferation predict influenza vaccine-induced antibody response. Eur J Immunol. 2014; 44: 285-295.
11. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009; 10: 116-125.
12. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS, Johnson SE, Milton A, Rajam G, Kasturi S, Carlone GM, Quinn C, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol. 2014; 15: 195-204.
13. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP, Khan N, Li GM, McCausland M, Kanchan V, Kokko KE, Li S, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011; 12: 786-795.
14. Tan Y, Tamayo P, Nakaya H, Pulendran B, Mesirov JP, Haining WN. Gene signatures related to B-cell proliferation predict influenza vaccine-induced antibody response. Eur J Immunol. 2014; 44: 285-295.
15. Franco LM, Bucasas KL, Wells JM, Niño D, Wang X, Zapata GE, Arden N, Renwick A, Yu P, Quarles JM, Bray MS, Couch RB, Belmont JW, Shaw CA. Integrative genomic analysis of the human immune response to influenza vaccination. eLife. 2013; 2: e00299.
16. Furman D, Jojic V, Kidd B, Shen-Orr S, Price J, Jarrell J, Tse T, Huang H, Lund P, Maecker HT, Utz PJ, Dekker CL, Koller D, Davis MM. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol. 2013; 9: 659.
17. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J, Herdman C, Bankaitis-Davis D, Nicholls N, Trollinger D, Tryon V. Stabilization of mRNA expression in whole blood samples. Clin Chem. 2002; 48: 1883-1890.
18. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003; 100: 9440-9445.